Latham & Watkins Advises Neumora Therapeutics in Strategic R&D Collaboration With Amgen To Accelerate Novel Precision Therapies for Brain Diseases

Amgen and Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering precision medicines for brain diseases, announced a strategic collaboration to advance neuroscience discovery, development and commercialization. The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities. In addition, Neumora has received a US$100 million equity investment from Amgen and acquired exclusive global rights to develop and commercialize Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.

Latham & Watkins LLP represents Neumora in the strategic collaboration agreement and equity investment with a Bay Area corporate team. Bay Area partner Brian Cuneo led the team on investment and corporate matters, and Bay Area Partner Judith Hasko led the team on collaboration matters, with Bay Area associate Peggy Ni. Advice was also provide on tax matters by Bay Area partner Kirt Switzer with Bay Area associate Jessica Chen and on antitrust matters by Washington, D.C. counsel Peter Todaro.